Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Summary

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.

Timeline

Start

2018-04-18

Primary completion

2020-01-31

Completion

2020-03-15

Outcome

Missed primary endpoint

registry analysis (other test); Amifampridine Phosphate - MuSK vs Placebo - MuSK vs Amifampridine Phosphate - AChR vs Placebo - AChR; p = 0.2196 NCT03304054 ↗

release “MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints” globenewswire.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amifampridine	Small molecule	10 mg	—

Indications